The 34 references in paper A. Mudunov, A. Ahundov, M. Bolotin, T. Braunschweig, А. Мудунов, А. Ахундов, М. Болотин, Т. Брауншвейг (2018) “Новые результаты исследования плоскоклеточного рака головы и шеи в отношении классификации и системной терапии. Расширенный обзор // An update on head and neck squamous cell carcinoma in respect to classification and systemic therapy. Extended review” / spz:neicon:ogsh:y:2018:i:1:p:48-55

1
Aldalwg M.A.H., Brestovac B. Human Papillomavirus Associated Cancers of the Head and Neck: An Australian Perspective. Head Neck Pathol
(check this in PDF content)
2
17;11(3):377–84. 2. Marur S., D'Souza G., Westra W.H., Forastiere A.A. HPV-associated head and neck cancer: a virus-related cancer epidemic. Lancet Oncol 2010;11(8):781–9. DOI: 10.1016/S1470-2045(10)70017-6.
(check this in PDF content)
3
Брауншвейг Т., Левандровски А., Смеетс Д., Болотин М.В. Плоскоклеточный рак головы и шеи: новые перспективы лечения? Опухоли головы и шеи 2013;(3):4–10. [Braunschweig T., Lewandrowski A., Smeets D., Bolotin M.V. Squamous cell carcinoma of the head and neck: new avenues of treatment? Opukholi golovy i shei = Head and Neck Tumors 2013;(3):4–10. (In Russ.)]. DOI: 10.17650/2222-1468-2013-0-3-4-10.
(check this in PDF content)
4
Forman D., de Martel C., Lacey C.J. et al. Global burden of human papillomavirus and related diseases. Vaccine 2012;30(5): F12–23. DOI: 10.1016/j.vaccine.2012.07.055.
(check this in PDF content)
5
Hammarstedt L., Lindquist D., Dahlstrand H. et al. Human papillomavirus as a risk factor for the increase in incidence of tonsillar cancer. Int J Cancer 2006;119(11): 2620–3. DOI: 10.1002/ijc.22177.
(check this in PDF content)
6
Ferlay J., Soerjomataram I., Dikshit R. et al. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer 2015; 136(5):E359–86. DOI: 10.1002/ijc.29210.
(check this in PDF content)
7
Bishop J.A., Guo T.W., Smith D.F. et al. Human papillomavirus-related carcinomas of the sinonasal tract. Am J Surg Pathol 2013;37(2):185–92. DOI: 10.1097/ PAS.0b013e3182698673.
(check this in PDF content)
8
Shaughnessy J.N., Farghaly H., Wilson L. et al. HPV: a factor in organ preservation for locally advanced larynx and hypopharynx cancer? Am J Otolaryngol 2014;35(1):19–24. DOI: 10.1016/j.amjoto. 2013.08.006.
(check this in PDF content)
9
Coordes A., Lenz K., Qian X. et al. Metaanalysis of survival in patients with HNSCC discriminates risk depending on combined HPV and p16 status. Eur Arch Otorhinolaryngol 2016;273(8):2157–69. DOI: 10.1007/s00405-015-3728-0.
(check this in PDF content)
10
Badoual C., Hans S., Merillon N. et al. PD-1-expressing tumor-infiltrating T cells are a favorable prognostic biomarker in HPV-associated head and neck cancer. Cancer Res 2013;73(1):128–38. DOI: 10.1158/0008-5472.CAN-12-2606.
(check this in PDF content)
11
Lewis J.S. Jr., Beadle B., Bishop J.A. et al. Human papillomavirus testing in head and neck carcinomas: Guideline from the College of American Pathologists. Arch Pathol Lab Med 2017; Dec 18. DOI: 10.5858/ arpa.2017-0286-CP.
(check this in PDF content)
12
Ndiaye C., Mena M., Alemany L. et al. HPV DNA, E6/E7 mRNA, and p16INK4a detection in head and neck cancers: a systematic review and meta-analysis. Lancet Oncol 2014;15(12):1319–31. DOI: 10.1016/S1470-2045(14)70471-1.
(check this in PDF content)
13
Ang K.K., Harris J., Wheeler R. et al. Human papillomavirus and survival of patients with oropharyngeal cancer. N Engl J Med 2010;363(1):24–35. DOI: 10.1056/ NEJMoa0912217.
(check this in PDF content)
14
Carozzi F., Gillio-Tos A., Confortini M. et al. Risk of high-grade cervical intraepithelial neoplasia during follow-up in HPVpositive women according to baseline p16INK4A results: a prospective analysis of a nested substudy of the NTCC randomised controlled trial. Lancet Oncol 2013;14(2):168–76. DOI: 10.1016/S14702045(12)70529-6.
(check this in PDF content)
15
Muller S., Khuri F.R., Konoet S.A. et al. HPV positive squamous cell carcinoma of the oropharynx. Are we observing an unusual pattern of metastases? Head Neck Pathol 2012;6(3):336–44. DOI: 10.1007/s12105-012-0355-6. tests), also other commercially available antibodies developed for research use were tested. Here, a significant number of well working antibodies could be found [25] and (table 3). Thus, several alternative antibodies are available with much less costs for the pathologist and patient. Сonclusion Squamous cell carcinomas of the head and neck are since recent years a field of plasticity and new approaches: after research discovered and established the connection of HPV infection and a subpopulation of HNSCC, the upcoming drug group of checkpoint inhibitors is abo
(check this in PDF content)
16
Adelstein D., Gillison M.L., Pfister D.G. et al. NCCN Guidelines Insights: Head and Neck Cancers, Version 2.2017. J Natl Compr Canc Netw 2017;15(6):761–70. DOI: 10.6004/jnccn.2017.0101.
(check this in PDF content)
17
Haddad R., Seiwert T., Pfister D.G. et al. Pembrolizumab after progression on platinum and cetuximab in head and neck squamous cell carcinoma (HNSCC): results from KEYNOTE-055. Ann Oncol 2016;27(6).
(check this in PDF content)
18
Barth C. Immunotherapy for Head and Neck Cancer: The Fourth Modality Has Arrived. Available at: http://www.ascopost. com/issues/march-10-2017/immunotherapy-for-head-and-neck-cancer-thefourth-modality-has-arrived/
(check this in PDF content)
19
Economopoulou P., Perisanidis C., Giotakis E.I., Psyrri A. The emerging role of immunotherapy in head and neck squamous cell carcinoma (HNSCC): anti-tumor immunity and clinical applications. Ann Transl Med 2016;4(9):173. DOI: 10.21037/atm.2016.03.34.
(check this in PDF content)
20
Chung C.H., Frampton G.M., Chalmers Z.R. et al. Genomic profiling of squamous malignancies across anatomic sites. J Clin Oncol 2017;35(15):11512. DOI: 10.1200/ JCO.2017.35.15_suppl.11512.
(check this in PDF content)
21
Blank C.U., Haanen J.B., Ribas A., Schumacher T.N. Cancer immunology. The “cancer immunogram”. Science 2016;352(6286):658–60.
(check this in PDF content)
22
Thallinger C., Fureder T., Preusser M. et al. Review of cancer treatment with immune checkpoint inhibitors: Current concepts, expectations, limitations and pitfalls. Wien Klin Wochenschr 2018;130(3–4):85–91. DOI: 10.1007/ s00508-017-1285-9.
(check this in PDF content)
23
Bahleda R., Braiteh F.S., Balmanoukian A.S. et al. Long-term safety and clinical outcomes of atezolizumab in head and neck cancer: phase la trial results. Ann Oncol 2017;28(5):v372–94. DOI: 0.1093/ annonc/mdx374.001a.
(check this in PDF content)
24
Zandberg D., Algazi A., Jimeno A. et al. Durvalumab for recurrent/metastatic (R/M) head and neck squamous cell carcinoma (HNSCC): Preliminary results from a single-arm, phase 2 study. Ann Oncol 2017;28(5):v372–94. DOI: 0.1093/ annonc/mdx374.
(check this in PDF content)
25
Scheel A.H., Dietel M., Heukamp L.C. et al. Harmonized PD-L1 immunohistochemistry for pulmonary squamous-cell and adenocarcinomas. Mod Pathol 2016;29(10):1165–72. DOI: 10.1038/ modpathol.2016.117.
(check this in PDF content)
26
Hirsch F.R., McElhinny A., Stanforth D. et al. PD-L1 immunohistochemistry assays for lung cancer: results from phase 1 of the Blueprint PD-L1 IHC Assay Comparison Project. J Thorac Oncol 2017;12(2):208– 22. DOI: 10.1016/j.jtho.2016.11.2228.
(check this in PDF content)
27
Ferris R.L., Clump D.A., Ohr J. et al. Phase I trial of cetuximab, intensity modulated radiotherapy (IMRT), and ipilimumab in previously untreated, locally advanced head and neck squamous cell carcinoma (PULA HNSCC). Ann Oncol 2017;28(Suppl 5). DOI: 10.1093/annonc/ mdx374.014.
(check this in PDF content)
28
BMS. Study of Nivolumab in Combination With Ipilimumab Compared to the Standard of Care (Extreme Study Regimen) as First Line Treatment in Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck (CheckMate 651). 2016. Available at: https://clinicaltrials.gov/ct2/show/ NCT02741570.
(check this in PDF content)
29
BMS. Study of Nivolumab in Combination With Ipilimumab Versus Nivolumab in Combination With Ipilimumab Placebo in Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck (CheckMate 714). 2018. Available at: https://clinicaltrials.gov/ct2/show/ NCT02823574.
(check this in PDF content)
30
NN. AstraZeneca Head and Neck Trials. 27.10.2016. Available at: https:// www.astrazeneca.com/media-centre/ press-releases/2016/astrazeneca-headand-neck-cancer-trials-27102016.html.
(check this in PDF content)
31
MSD. Pembrolizumab in Combination With Cisplatin and Intensity Modulated Radiotherapy (IMRT) in Head and Neck Cancer. 2016. Available at: https:// clinicaltrials.gov/ct2/show/NCT02777385.
(check this in PDF content)
32
BMS. An Investigational Immuno-therapy Trial of Nivolumab, or Nivolumab Plus Ipilimumab, or Nivolumab Plus Platinumdoublet Chemotherapy, Compared to Platinum Doublet Chemotherapy in Patients With Stage IV Non-Small Cell Lung Cancer (NSCLC) (CheckMate 227). 2015. Available at: https://clinicaltrials.gov/ct2/ show/NCT02477826.
(check this in PDF content)
33
BMS. Oropharyngeal Tumor Induction Chemotherapy and Response-stratified Locoregional Therapy Trial in Order to Minimize Long-term Adverse Events (OPTIMA II). 2017. Available at: https:// clinicaltrials.gov/ct2/show/NCT03107182.
(check this in PDF content)
34
Kintsler S. et al. PD-L1 Immunohistochemical stains and comparison of 10 available antibodies and their staining behaviour and costs. Mod Pathol, under Review 2018.
(check this in PDF content)